Asthma Drugs Market Global Analysis and Forecast 2021, 2028

report image

Asthma Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Medications (Quick Relief Medications and Long-Term Control Medications), Route of Administration (Inhaled, Prefilled Syringes/Vials, and Others), and Distribution Channels (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)

Publication Month: Apr 2022 | Report Code: TIPRE00021879 | No. of Pages: 191 | Category: Pharmaceuticals | Status: Published

The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021–2028.

Asthma is a lung disease that affects people of all ages. It produces wheezing and makes breathing difficult. Exposure to an allergy or irritant, infections, exercise, emotional stress, and other conditions are all potential triggers. When the symptoms of asthma become unbearable, an asthma attack ensues. Attacks can happen out of nowhere and range from mild to life-threatening. Asthma is managed with rescue inhalers to treat symptoms and controller inhalers that prevent symptoms. Severe cases may require longer-acting inhalers that keep the airways open (formoterol, salmeterol, tiotropium) and inhalant steroids. Asthma medication comes in several forms, including tablets, injections, liquids, and inhalers, and it falls into two groups, such as bronchodilators and anti-inflammatories.

The asthma drug market is segmented on the basis of medication, route of administration, distribution channel, and geography. The market, based on geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The asthma drugs market report offers insights and in-depth analysis of the market, emphasizing parameters such as market size, trends, and dynamics; technological advancements in the market; and the analysis of the competitive landscape of the leading market players in the asthma drugs market. 

Strategic Insights

Report Coverage - Asthma Drugs Market
Report CoverageDetails
Market Size Value inUS$ 24,239.17 Million in 2021
Market Size Value byUS$ 34,136.10 Million in 2028
Growth rateCAGR of 5.0 % from 2021 to 2028
Forecast Period2021-2028
Base Year2021
No. of Pages191
No. of Tables88
No. of Charts & Figures81
Historical data availableYes
Segments coveredMedications, Route of Administration, and Distribution Channels
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

A few factors such as the growing environmental implications & genetic implications of air pollution, more vulnerability in specific ethnic groups, growing exposure to coarse particulate matters, growing prevalence of physiological disorders harboring asthma are expected to have a significant short-, mid-, and long-term impact on the asthma drugs market in the coming years. However, unmet medical needs and lack of treatment adherence hamper the market growth. The market report identifies opportunities and future market trends that can have possible impacts on market growth.

Lucrative Regions in Asthma Drugs Market

Lucrative Regions in Asthma Drugs Market

Get more information on this report :


Market Insights

Growing Environmental Implications & Genetic Implications of Air Pollution

Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyperresponsiveness, and airways inflammation. According to a review paper titled “Impact of Air Pollution on Asthma Outcomes” by Tiotiu et.al., air pollution hampered asthma outcomes in adults and children. Air pollution from traffic, nitrogen dioxide (NO2), and secondhand smoking (SHS) are all substantial risk factors for the development of asthma in children. Asthma symptoms, exacerbations, and decreased lung function can be triggered by exposure to outside pollution.

In the US, exposure to air pollution continues to be associated with asthma. This severe and life-threatening chronic respiratory condition impacts the quality of life of more than ~23 million American citizens. Air pollution can aggravate asthma symptoms, triggering asthma attacks among people. Children with asthma, which affects ~6 million children in the US, are particularly vulnerable to pollution.

A new study financed by the Environmental Protection Agency (EPA) analyzed the link between air pollution and asthma. While experts cannot determine the primary asthma-causing agent due to air pollution, evidence suggests that it suppresses genes that control the immune system to distinguish between an allergen and a hazardous foreign substance, such as a virus or bacteria. The immune system then goes into overdrive, triggering an inflammatory reaction regardless of whether the drug is toxic, resulting in asthma.

Researchers from Stanford University's Children's Center investigated the effect of air pollution on two genes involved in immunological tolerance in children from an area with high levels of pollution. They discovered that short- and long-term exposure to high amounts of carbon monoxide (CO), NO2, and PM2.5 (particulate matter) were linked to changes in these two genes, which caused asthma. These findings focused on the epigenetic impacts of air pollution exposure and could help in the development of preventative asthma medicines.

Each of these asthma research has improved the understanding of asthma in children and supplied crucial information to the EPA that can be used to protect human health and the environment. Through these research works, the drug discovery and development for asthma is being expedited, which is driving the asthma drug market.

Medication Type-Based Insights

The global asthma drugs market, based on medications, is bifurcated into quick relief medications and long-term control medications. The long-term control medications segment is expected to hold a larger share of the market in the coming years. However, the quick relief medications segment is expected to register a higher CAGR during the forecast period.

Asthma Drugs Market, by Medication – 2021 and 2028

Asthma Drugs Market, by Medication – 2021 and 2028

Get more information on this report :

Route of Administration-Based Insights

Based on route of administration, the asthma drugs market is segmented into inhaled, prefilled syringe/vials, and others. The inhaled segment held the largest share of the market in 2021 and is expected to hold a significant share during the forecast period. However, the prefilled syringe/vials segment is expected to register the highest CAGR from 2021 to 2028.

Distribution Channel-Based Insights

Based on distribution channel, the asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The retail pharmacies segment is expected to hold the largest share of the market during the forecast period. However, the online pharmacies segment is expected to register the highest CAGR during 2021–2028.

Various companies operating in the asthma drugs market adopt strategies such as product launches, mergers and acquisitions, collaborations, product innovations, and product portfolio expansions to expand their footprint worldwide, maintain a brand name, and meet growing consumer demands. Some of the leading players present in the market are AstraZeneca; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline PLC; Boehringer Ingelheim International GmbH; Merck & Co., Inc.; Koninklijke Philips NV; Sanofi; Pfizer Inc.; Novartis AG; and Abbott.

Frequently Asked Questions

Asthma is a lung disease that affects people of all ages. It produces wheezing and makes breathing difficult. Exposure to an allergy or irritant, infections, exercise, emotional stress, and other conditions are all potential triggers. When the symptoms of asthma become unbearable, an asthma attack ensues. Attacks can happen out of nowhere and range in severity from mild to life-threatening. Asthma is managed with rescue inhalers to treat symptoms and controller inhalers that prevent symptoms. Severe cases may require longer-acting inhalers that keep the airways open (formoterol, salmeterol, tiotropium), as well as inhalant steroids. Asthma drugs come in several forms, including tablets, injections, liquids, and inhalers; and it falls into two groups: bronchodilators and anti-inflammatories.
The global asthma drugs market is being driven by factors such as growing environmental implications & genetic implications of air pollution, more vulnerability in specific ethnic groups, growing exposure to coarse particulate matters, and the growing prevalence of physiological disorders harboring asthma.
The unmet medical needs and the lack of treatment adherence are the leading restraints that will hinder the asthma drugs market growth.
The asthma drugs market comprises of players that include AstraZeneca, TEVA PHARMACEUTICAL INDUSTRIES LTD, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Koninklijke Philips N.V., Sanofi, Pfizer Inc., Novartis AG, and Abbott are among others.
The asthma drugs market on the basis of medication is bifurcated into quick relief medications and long-term control medications. In 2021, the long-term control medications segment accounted for a larger share in the global asthma drugs market.
On the basis of route of administration, the asthma drugs market is segmented into inhaled, prefilled syringe/vials, and others. The inhaled segment is expected to hold the largest share from 2021 to 2028. However, the prefilled syringe/vials segment is expected to grow at the highest CAGR during the forecast period.

The List of Companies - Asthma Drugs Market

  1. AstraZeneca
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  3. GlaxoSmithKline plc
  4. Boehringer Ingelheim International GmbH
  5. Merck & Co., Inc.
  6. Koninklijke Philips NV
  7. Sanofi
  8. Pfizer Inc.
  9. Novartis AG
  10. Abbott
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the asthma drugs market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global asthma drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TIPRE00021879
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount